SIIM20

VIRTUAL MEETING

Powered by SIIMU Online Learning

CELEBRATING

YEARS

June 24–26 *Reimagining the Future.*

AI in the Digital Pathology World

High-Throughput Truthing Project (HTT)

Thursday, June 25 | 8:00 am – 9:30 am

Brandon D Gallas, PhD

Division of Imaging, Diagnostics, and Software Reliability Office of Science and Engineering Laboratories Center for Devices and Radiological Health







None

 The mention of any commercial products herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.



High-throughput truthing (HTT) Collaborators

Collaboration of Volunteers

Engage stakeholders through the Alliance for Digital Pathology



Involve experts & the community.



Powered by SIIMU Online Learning

HTT Core Collaborators



Project mgmt.

- Sarah Dudgeon, MPH
 - FDA/CDRH/OSEL/DIDSR

caMicroscope team

- Ashish Sharma, PhD
 - Emory University Department of Biomedical Informatics
- Joel Saltz, MD PhD
 - Dept. of Biomedical Informatics, Stony Brook Medicine
- Nan Li, MS
 - Dept. of Biomedical Informatics, Stony Brook Medicine

PathPresenter team

- Matthew Hanna, MD
 - Memorial Sloan Kettering, New York, NY
- Rajendra Singh, MD
 - Icahn School of Medicine at Mt Sinai
- Krushnavadan Acharya, MCA
 - o PathPresenter

Slides and Clinical

- Roberto Salgado
 - Peter Mac Callum Cancer Center; GZA-ZBA Hospitals
 - International Working Group for TILs in Breast cancer
- Denis Larismont
 - o Institut Jules Bordet

Statistics

- Si Wen
 - FDA/CDRH/OSEL/DIDSR
- Manasi Sheth
 - FDA/CDRH/OPEQ/OCEA/Biostatistics
- Chava Zibman
 - FDA/CDRH/OPEQ/OCEA/Biostatistics
- Weijie Chen, PhD
 - FDA/CDRH/OSEL/DIDSR

Committee

- Mohamed Amgad, MSc
 - Emory University School of Medicine, Atlanta, GA
- Rajarsi Gupta, MD, PhD
 - Renaissance School of Medicine and Dept. of Biomedical Informatics, Stony Brook Medicine
- Steven N. Hart, PhD
 Mayo Clinic, Rochester, MN
- Joe Lennerz, MD, PhD
 - Massachusetts General Hospital, Boston, MA
- Richard Huang, MD, MS
 - Massachusetts General Hospital, Boston, MA
- Anant Madabhushi, PhD
 - Case Western Reserve University
- Kyle J. Myers, PhD

 FDA/CDRH/OSEL/DIDSR
- Open door policy



High-throughput truthing (HTT) Project

Demonstration project

- Collect multi-reader image annotations to establish biomarker truth
- Annotations support validation of an algorithm
- Pursue an FDA <u>Medical Device Development Tool</u> Qualification

 Application: Stromal Tumor Infiltrating Lymphocytes are prognostic in breast cancer











- QuantitativeBiomarker
- Density: 0-100





Pathologist

- o Takes time
- Requires training
- o Noisy
- Board Certification

Algorithm

- o Fast
- Requires training
- \circ Reproducible
- Regulatory permission



Powered by SIIMU Online Learnin











"Truth by pathologist" **Reduce and Account** for Pathologist **Pathologist Variability** o Takes time **Requires training** 0 Noisy Ο Board Certification Algorithm • Fast **Evaluate performance Requires training** Ο **Requires truth** Reproducible Ο **Regulatory permission** 0







Pathologist

- o Takes time
- o Requires training
- o Noisy
- Board Certification

Algorithm

- o Fast
- Requires training
- Reproducible
- Regulatory permission

"Truth by pathologist"

- Additional training
- Multiple pathologists per region / image
 - Sophisticated analysis

Evaluate performance Requires truth



Patch to Whole Slide Image





Zoom Out



siim.org | #SIIM20 | @SIIM_Tweets

Whole Slide Images: Digital Scans of Glass slides





- Breast Cancer Biopsies
- Square Regions of Interest control the evaluation areas

Current selection by pathologist:

- Areas in tumor (~50%)
- Areas in tumor margin (~20%)
- Other (~30%)

Whole Slide Images: Digital Scans of Glass slides





- Breast Cancer Biopsies
- Square Regions of Interest control the evaluation areas

Study to prepare the study. Cover the range of scores.



Whole Slide Image to Patient





Zoom Out



siim.org | #SIIM20 | @SIIM_Tweets

Patients



Subgroup Description		Planned for MDDT?
Age	<40 years old	Yes
	40-60 years old	Yes
	>60 years old	Yes
Breast Cancer Subtypes	Luminal A	Maybe
	Luminal B	Maybe
	Triple-negative	Yes
	HER2 positive	Maybe
	Normal-like	Maybe
	0	Yes
Breast Cancer Stages	I	Yes
	П	Yes
	Ш	Yes
	IV	Yes
Patients After	Therapy 1	No
	Therapy 2	No
Therapy	Therapy 3	No

TILs always look the same. Background "context" looks different.

- Regulatory submission
- Define the patient population
- HTT project can't afford to sample and annotate all subgroups
- Algorithm manufacturer responsible for gaps



Pathology vs. Radiology

Truth for pathology is challenging

- Pathology images much larger
 - Truthing more burdensome ... more area!

Focus on regions of interest

 Radiology truth often established by pathology evaluation of biopsy ...
 Agreement with multiple

pathologists



http://www.hologic.ca/image-analytics#overlaycontext=closeup-peerview-cad



siim.org | #SIIM20 | @SIIM_Tweets



Pathology vs. Radiology

Truth for pathology is challenging

- Pathology images much larger
 - Truthing more burdensome ... more area!

Focus on regions of interest

 Radiology truth often established by pathology evaluation of biopsy ...
 Agreement with multiple

pathologists

- Alternate tissue stains
 - Done on adjacent tissue or requires restaining

Not the same tissue Can damage the tissue



http://www.hologic.ca/image-analytics#overlaycontext=closeup-peerview-cad



Silv20 VIRTUAL MEETING Powered by SIIMU Online Learning

Pathology vs. Radiology

Truth for pathology is challenging

- Pathology images much larger
 - Truthing more burdensome ... more area!

Focus on regions of interest

Not the same tissue

Can damage the tissue

 Radiology truth often established by pathology evaluation of biopsy ...
 Agreement with multiple

pathologists

- Alternate tissue stains
 - o Clear and restain or adjacent tissue
- Outcomes
 - Complicated to coordinate
 - o Cost time and money
 - Several steps removed from tissue

http://www.hologic.ca/image-analytics#overlaycontext=closeup-peerview-cad







Update: Choices & Challenges





Total Obs 2394

Data-collection test run

- Alliance Meeting
- USCAP Annual Meeting
- Feb. 28, 2020

Four workstations

- 2 microscopes
- 2 digital platform

64 slides (balance sampling within and across specimens)

- 8 batches of 8 slides
- 10 ROIs per slide
- 30 minute sessions



Powered by SIIMU Online Learning

- Histogram of Biomarker Scores
- Many slides yield LOW biomarker scores









- Histogram of Biomarker Scores
- Many slides yield LOW biomarker scores
- Some slides yield LOW to MODERATE biomarker scores







- Histogram of Biomarker Scores
- Many slides yield LOW biomarker scores
- Some slides yield LOW to MODERATE biomarker scores
- Some slides yield LOW to HIGH biomarker scores





- Histogram of
 Biomarker Scores
- One reader
- All 64 slides
- 10 ROIs per slide
- Oversampling low scores



sTIL densities





Agreement: Start with a scatter plot

- Two readers, CAmicroscope, batch001
- Plots scaled log base 10
- Circle size proportional with number of observations





Powered by SIIMU Online Learning

Combine to

Agreement: Consider all pairs of readers





siim.org | #SIIM20 | @SIIM_Tweets



Agreement: Consider all pairs of readers





siim.org | #SIIM20 | @SIIM_Tweets









Truth by pathologists

Pathologist evaluations are noisy Reduce variability with

- Training
- Multiple pathologists per case



Summary





Truth by pathologists

Pathologist evaluations are noisy Reduce variability with

- Training
- Multiple pathologists per case



Data Sampling

Range of biomarker scores Regions within an image Images from different patient subgroups



Summary





Truth by pathologists

Pathologist evaluations are noisy Reduce variability with

- Training
- Multiple pathologists per case



Data Sampling

Range of biomarker scores Regions within an image Images from different patient subgroups



Data analysis

Account for known sources of variability and correlations Multi-reader, multi-case analysis Clustered and nested data



29

So sad. Not enough time to discuss.



• Statistical methods

- Clinical context and use case
- FDA's <u>Medical Device Development</u> <u>Tool</u> Program
- Device advice
 - <u>https://ncihub.org/groups/eedap</u> <u>studies/wiki/DeviceAdvice</u>



Closing



- We are collecting data to
 - Build collaborative relationships
 - o Investigate methods and tools
 - Support the evaluation of AI/ML

We hope to

- Inform regulatory decision making
- o Improve submissions
- Support and enable interoperability



More information



Learn about the project

High-throughput Truthing - Year 2

by Brandon D. Gallas

E Article 🖌 Edit 🗢 Comments 💿 History

O Delete

HighthroughputTruthingYear1 HighthroughputTruthingYear3

Year 2: High-throughput truthing of microscope slides to validate artificial intelligence algorithms analyzing digital scans of pathology slides: data (images + annotations) as an FDA-qualified medical device development tool (MDDT).

- Here is an overview presentation given at Pathology Informatics.
- "A Collaborative Project to Produce Pathologist Annotations□to Evaluate Viewers and Algorithms."
- 20190508-HTToverviewGallasAtPlsummit-v4.pdf (2 MB, uploaded by Brandon D. Gallas 1 year 8 hours ago)
- Here is an executive summary (four slides) of the project.
- 20190402-HTTexecSummaryPublic.pdf (193 KB, uploaded by Brandon D. Gallas 1 year 1 month ago)
- Here is a project overview presentation given Nov.-Dec. 2018 to FDA/CDRO/OSEL management, the 2 www.TILsinbreastcancer.org working group, project collaborators, and others.
 - 20190402-HTToverviewPublic.pdf (348 KB, uploaded by Brandon D. Gallas 1 year 1 month ago)
- Here is a link to the original proposal for internal funding

 ^C Link to full proposal submitted 10/19/2018. Funding awarded in March 2019.
- Link to list of collaborators
- Link to updates

Project Overview

Pitch: We are launching a project to crowdsource pathologists and collect data (images + pathologist annotations) that can be qualified by the FDA/CDRH medical device development tool program (MDDT). The MDDT qualified data would be available to any algorithm developer to be used to validate their algorithm performance in a submission to the FDA/CDRH.

Notice the year 2 title changed to emphasize "data (images + annotations) as an FDA-qualified medical device development tool (MDDT)" if we can https://nciphub.org/groups/eedapstudies/wiki/HighthroughputTruthingYear2

Participate in Data Collection



https://nciphub.org/groups/eedapstudies/wiki/HighthroughputTruthingYear3